ClinicalTrials.gg
Not yet recruitingNCT06427200Updated May 24, 2024

Efficacy and Safety of Lactoferrin in Heart Failure Patients

A Phase 4 interventional study of oral Iron and Lactoferrin in Heart Failure With Reduced Ejection Fraction, sponsored by Cairo University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by Cairo University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing iron in Iron Deficiencies — 5 open to participants now, 7 under way, none of them phase 3. Iron · Iron Deficiencies.

Planned enrollment
10th of 21
114 · median 111
Started
2024
with 1 other
Phase 4
4 of 21
1 open now
Registered
15th of 21
by date
Lead sponsor
2 of 21
Cairo University

Among the 21 studies testing iron in Iron Deficiencies, this one is the 10th largest by planned enrollment, is one of 2 that started in 2024, is one of 4 in phase 4, and was the 15th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

5 of the 21 studies testing iron in Iron Deficiencies are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About iron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing iron in Iron Deficiencies, or all of them as a file.
02

Study summary

This study will be conducted to determine the efficacy and safety of lactoferrin versus oral iron versus lactoferrin plus oral iron as an add on therapy in reduced ejection fraction heart failure patients with iron deficiency.

•Patients will be randomly distributed into the three groups

  • All patients will be subjected to baseline data assessment
  • Follow up after 12 weeks
03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Keywords

  • Lactoferrin
  • oral iron
  • reduced ejection fraction
  • iron deficiency
  • heart failure
  • clinical trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-65 years old.
  2. Chronic heart failure (> 6 months duration) with reduced defined as LVEF ≤ 40%.
  3. -class II or III or IV with stable symptoms for at least the past 3 months.
  4. Stabilized on beta blockers, renin-angiotensin system inhibitor (ACEI/ARB) or angiotensin receptor-neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs) and sodium-glucose co-transporter 2 Inhibitors (SGLT2i) and diuretics as needed.
  5. No dose changes of heart failure drugs during the last 2 weeks (exception: diuretics)
  6. No introduction of a new heart failure drug class during the last 4 weeks.
  7. Iron deficiency: serum ferritin level of 15 to 100 ng/mL or a serum ferritin level of 101 to 299 ng/mL with transferrin saturation of less than 20%.

Exclusion criteria

Exclusion Criteria:

    1. Arrythmia including atrial fibrillation (AF) with poorly controlled ventricular rate at rest (> 100 beats/min).

      1. Recent cardiac related hospitalizations in the past 3 months. 3. Known active infection. 4. Associated chronic medical disorder (chronic kidney disease ( \< 60 ml/min), liver disease ( or AST > 3× ), peptic ulcer or chronic blood loss).
      1. Associated bleeding disorder. 6. Previous iron supplement in past 3 months. 7. Anemia requiring blood transfusion ( (Hb) \< 7 g/dL). 8. Folic acid or vitamin B12 deficiency. 9. to lactoferrin or iron. 10. Haemoglobinopathies (G6PD, thalassemia's, sickle cell disease). 11. Pregnancy and lactation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    group "oral iron"

    Drug: oral Iron

  • Experimental
    group "lactoferrin"

    Drug: Lactoferrin

  • Experimental
    group "lactoferrin and oral iron"

    Drug: lactoferrin and oral iron

Interventions

  • DrugIronStudies of IronIron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    oral iron once daily during or after meals as add-on therapy for 12 weeks.

  • lactoferrin twice daily before meals as add-on therapy for 12 weeks.

  • Druglactoferrin and oral iron

    Drug pages: LactoferrinStudies of LactoferrinLactoferrin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IronStudies of IronIron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in health-related quality of life (HR-QoL)

    • Change in health-related quality of life (HR-QoL) as evaluated by Minnesota Living with Heart Failure Questionnaire (MLHFQ) minimum score:0 maximum score:105 minimum score is a better outcome

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Jul 2027, 36 months later.

Of 26 phase 4 interventional studies under Iron Deficiencies, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2024
First posted
May 23, 2024
StartEst.
Jul 2024
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06427200
Lead sponsor
Cairo University
Responsible party
reham mohamed saied salem (Teaching assistant at Faculty of Pharmacy Cairo University, Cairo University) — Principal investigator
First posted
May 23, 2024
Start date
Jul 2024 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
May 24, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iron · Lactoferrin

Start the discussion